天津医药

• 临床论丛 •    

Bcl-2、Ki-67在前列腺癌组织中的表达及临床意义

赵朋1,于斌1,刘德祥1,胡海龙2,白铁男2,孙光2   

  1. 1. 天津市第四中心医院泌尿外科
    2. 天津医科大学第二医院
  • 收稿日期:2012-11-01 修回日期:2013-03-28 出版日期:2013-10-15 发布日期:2013-10-15
  • 通讯作者: 赵朋

Expression of Bcl-2、Ki-67 protein in prostatic carcinoma and their clinical significance

  • Received:2012-11-01 Revised:2013-03-28 Published:2013-10-15 Online:2013-10-15
  • Contact: pengpeng zhao

PDF (PC)

2236

摘要：

 

关键词: 前列腺肿瘤, 癌, 基因, bcl-2, Ki-67抗原, 免疫组织化学

Abstract: Abstract Objective：To study the expression and clinical significance of Bcl-2 and Ki-67 in prostatic carcinoma．Methods：Immunohistochemical ABC was used to determine the expression of Bcl-2 and Ki-67 in 20 cases of BPH tissue and 60 cases prostatic carcinoma．Results: The positive incidences of Bcl-2 and Ki-67 expression in BPH tissue were5% 、15%,and prostatic carcinoma were 63%±48.2%、70%±46.9%.The expressionof Bcl-2 and Ki-67 correlated to preoperative serum prostate-specific antigen level，extraprostatic extension，the degree of histobogical grade and clinical stage(P<0.05).The expression of Bcl-2 had a positive relation with expression of Ki-67（r=0.167 P<0.05）. Conclusion；The combined detection of Bcl-2 and Ki-67 proteins can be used to evaluate the incidence of prostate carcinoma development, prognosis, and provide an important basis for drug treatment .